Pipeline Insight: Orphan Diseases in CNS - Amyotrophic Lateral Sclerosis

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2007-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of pipeline drugs.


Scope

  • Scenario based analysis and forecasts of the commercial potential of the ALS market to 2016.
  • Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs.
  • Strategic recommendations for maximizing the potential of drugs in this niche orphan disease market.
  • Indication-specific sales forecasts of marketed and key pipeline drugs to 2016.


    • Report Highlights
    A lack of new entrants, and the possibility of polytherapy, results in Sanofi-Aventis's Rilutek (riluzole) dominating the market until patent expiry in 2012-13 in Datamonitor's base scenario.

    Orphan drug status, rapid uptake following launch, limited risk to the company's share price if drugs fail, and possible indication expansions make long-term investment in ALS a commercially viable option.

    A scenario forecast based on the clinical success of rhIGF-1 (recombinant human insulin-like growth factor I) related therapies reveals a potentially lucrative market. However, with a high attrition rate of ALS Phase III clinical trials, and mixed efficacy data in Phase II, the results of currently underway studies will be pivotal.


    Reasons to Purchase

  • Access the lucrative potential of this underdeveloped neurodegenerative disease therapeutic market.
  • Benchmark key late-stage compounds against the current leading therapy Sanofi-Aventis's Rilutek (riluzole).
  • Understand the opportunities in this market based on the comments of interviewed key opinion leaders.

    • Table of Contents

    Other users found this report page using the following search terms: Amyotrophic Lateral Sclerosis als als aventis phase rilutek sclerosis clinical amyotrophic cns lateral sanofi

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.